Smarter Genomics.
Faster Insights. Greater Confidence.
AI-powered NGS bioinformatics
driving personalized medicine forward.
Streamline germline and somatic analyses across panels, exomes, and genomes, supporting short and long-read sequencing. Our platform is wet lab and sequencer-agnostic, purpose-built for you.
Our DiagAI Score pinpoints the most relevant variants instantly, using advanced pathogenicity prediction, phenotype matching, and expert-driven rules—so you get clear, actionable results at lightning speed.
SeqOne Flow automates your entire data pipeline—from file transfer to analysis initiation. Integrated with LIMS and IT systems, it eliminates manual work, speeds up turnaround times, and keeps everything running smoothly.
Clinically validated. Premium annotation. Uncompromising precision. SeqOne integrates top-tier databases, including CKB and COSMIC, to deliver high-confidence insights, so you can make decisions with certainty.
We put our customers at the center of everything we do. SeqOne adapts to your needs—integrating your feedback and the latest genomics advancements to keep your workflows efficient, seamless, and always up to date.
Your data stays yours—never shared, never sold. Our patented double-encryption system secures each patient file with a unique key for maximum data protection. You stay safe, compliant, and in control.
The SeqOne Platform is an in vitro diagnostic medical device, CE-IVD Class C certified under IVDR. The company is certified under ISO 13485 for medical device manufacturer, and under ISO 27001 and HDS for information security and health data hosting.All certificates are available at trust.seqone.com.
Identify acquired mutations in cancers.
Pinpoint germline variants.
Detect microbial pathogens.
Validate SeqOne with your own data, expert support, and zero commitment.
Pay-per-analysis with no hidden fees or volume constraints.
Access field specialists, multi-lingual assistance and hands-on guidance.
SeqOne’s Fall 2026 Release brings a new PGx module, SomaHRD v2 and 80+ features and improvements, all IVD from day one, so labs can give more patients a clear answer, sooner, on a single platform.
C5 is the BSI’s cloud security standard, required in Germany for health data. SeqOne’s cloud services now hold a C5:2020 Type 2 attestation, with security controls independently tested in day-to-day operations.
Valencia’s General University Hospital brought HRD testing in-house with Agilent and SeqOne. A 30-case study showed matching classifications vs. commercial assays, fewer inconclusive results, and turnaround cut from ~20 to 6-7 days.
SomaHRD v2 reaches 97.1% concordance with Myriad MyChoice CDx and a PFS hazard ratio of 0.23, with a 4.8% non-conclusive rate and results in 41 minutes.
Rewatch our webinar with Uppsala University Hospital: how one lab unified short-read, long-read, and array workflows on a single platform, and how transparent AI ranks variants so the geneticist stays in control.
A clear DPYD test missed a 545kb deletion that caused severe chemotherapy toxicity in a cancer patient. SeqOne's copy number analysis helped confirm what standard testing couldn't see.
Precision medicine still overlooks most of the world. See how Gencell is closing that gap, one exome at a time.
Every exome hides thousands of variants. See how DiagAI found the right one in 94.9% of cases, now peer-reviewed.
Revisit the three posters presented by the SeqOne team at ESHG 2026.
Genomic data is expanding rapidly. AI offers vital tools to streamline variant interpretation, but deploying it requires absolute clinical trust, rigorous compliance, and transparent decision-making.
How our Clinical Interpretation Services helped nearly 900 families receive timely genomic analysis, and what a six-year partnership tells us about the future of clinical genomics.
Meet UP²-SV: a dedicated AI pathogenicity classifier for structural variants, trained on 65,000+ ClinVar SVs and validated on a clinical cohort with 97.6% sensitivity. AI-powered prioritization now spans the full variant spectrum.
Sequencing at scale is solved. Consistent interpretation isn't. See how one university hospital modernized their solid tumor NGS workflow and validated it for routine clinical use.
Our most ambitious release yet. 72 features and improvements, all IVDR-certified from day one, so every advance reaches patients without delay..
A Spanish hospital ended a patient's 30-year diagnostic odyssey by combining Agilent's advanced exome sequencing with SeqOne's AI platform, uncovering a rare DMD gene duplication that had eluded detection for decades.
Validated on 565 Genomics England WGS cases, DiagAI achieves impressive performance, with full explainability and CE-IVD certification.
Genekor Medical, a Romanian diagnostics lab, uses SeqOne's platform to make HRD testing a routine clinical workflow. Using shallow whole genome sequencing and automated FASTQ-to-GIS analysis, they've cut complexity and costs, proving that reliable precision oncology testing is achievable for regional labs beyond major European hubs.
Genomic data is abundant. Interpreting it is the challenge faced by most modern labs today. Watch our webinar for a practical framework on choosing the right bioinformatics platform.
Revolutionizing clinical diagnostics: Uppsala University Hospital and SeqOne build a unified, future-proof genomics lab.
Decoding the whole genetic code: how one lab mastered Whole Genome Sequencing to deliver life-changing rare disease diagnoses.
Spanish diagnostic leader Cerba Internacional used the AI-driven SeqOne platform to overcome NGS data bottlenecks.
New integrated tools enable comprehensive liquid biopsy analysis, covering both somatic variants and epigenetic signatures in a single workflow.
Rewatch our webinar to discover how molecular signatures like HRD and IGHV mutational status are used in clinical practice to deliver personalized oncology.
Strategic acquisition of UK genomics leader Congenica reinforces SeqOne market position and footprint - servicing over 160 labs in 30+ countries.
Rewatch our webinar to discover how AI is revolutionizing clinical genomics, speeding up variant interpretation, and enhancing diagnostic accuracy.
Jonathan Sheldon, a distinguished bioinformatics and digital health executive (ex-QIAGEN, Oracle), joins SeqOne's board, bolstering their global personalized medicine expansion.
SeqOne and Agilent Announce Strategic Collaboration to Advance Liquid Biopsy Data Analysis for Oncology Applications
New capital from Supernova Invest, alongside existing partners Elaia, Omnes, and Merieux Equity Partners, will accelerate SeqOne’s mission to transform genomic diagnostics worldwide, focusing on international expansion, U.S., and strategic growth.
SeqOne's SomaHemato offers robust, validated IGHV analysis for CLL prognosis, overcoming NGS short-read limits for precise clinical insights.
Strategic acquisition bolsters SeqOne's multi-omics capabilities and expands service offerings with ISO-certified sequencing platform.
SeqOne's DiagAI HPO automates extraction of HPO terms from clinical notes using AI, streamlining phenotype-driven genomic analysis with multi-language support.
Professor Anne-Sophie Lèbre of CHU de Reims uses SeqOne for rare disease and oncology genomics, enabling rapid, precise variant interpretation.
Here, 30 well-characterized clinical germline samples were studied with adaptive sampling to enrich the full sequence of 152 cancer predisposition genes. Sequencing was performed on Oxford Nanopore (ONT) R10.4.1 MinION flowcells with the Q20+ chemistry.
DiagAI uses inheritance & quality rules based on real diagnostic data, enabling clinicians to understand AI recommendations and collaborate on system improvement.
SeqOne Platform gets IVDR Class C medical device certification for NGS analysis in oncology and rare diseases, validating quality and safety.
APHM and SeqOne partner to automate exome sequencing with AI, processing up to 2,000 rare disease samples yearly for better diagnostics.
SeqOne launches DiagAI Score, a 0-100 metric for ranking genetic variants' disease-causing potential, combining AI power with human expertise for faster diagnosis.
Solving the structure of mRNA transcripts is a major challenge for both research and molecular diagnostic purposes. Current approaches based on short-read RNA sequencing and RT-PCR techniques cannot fully explore the complexity of transcript structure.
SeqOne’s HRD platform enables North West GLH to conduct in-house genomic instability testing for ovarian cancer.
MGI and SeqOne partner to develop genomic analysis solutions, combining MGI's sequencing tech with SeqOne's AI-powered platform.
SeqOne Cloud now supports Agilent CGH MicroArrays, offering AI-powered CNV annotation, ACMG classification, and seamless Cartagenia migration.
GenomeAlert! reevaluates genetic variant classifications monthly against ClinVar to ensure accurate patient diagnoses and treatment.
A new partnership delivers end-to-end genome nanopore sequencing solutions for clinical applications in rare disease and oncology.
The PAOLA-1/ENGOT-ov25 trial showed that maintenance olaparib plus bevacizumab increases survival of advanced ovarian cancer patients with homologous recombination deficiency (HRD).
Martin Dubuc appointed as SeqOne Genomics CEO, Nicolas Philippe becomes President & CPSO to drive global clinical genomics expansion.
SeqOne launches HRD test for ovarian cancer patients, validated with PAOLA-1 cohort. Clinical validation shows comparable survival benefits to Myriad myChoice® CDx.
Using nanopore sequencing, we showed the feasibility and impact of rapid genomic screening for managing thrombotic microangiopathies in 18 prospective cases, achieving diagnoses in <3 days. We compared the results with standard exome sequencing, cost efficiency, and complement blockade initiation.
Despite the availability of whole exome (WES) and genome sequencing (WGS), chromosomal microarray (CMA) remains the first-line diagnostic test in most rare disorders diagnostic workup, looking for copy number variations (CNVs), with a diagnostic yield of 10%–20%.
This monocentric study included fifteen children under a year old in intensive care with suspected monogenic conditions for rapid trio exome sequencing (rES) between April 2019 and April 2021.
Poly(ADP-ribose) polymerase 1 inhibitor (PARPi) agents can improve progression-free survival of patients with breast cancer who carry a germline BRCA1 or BRCA2 pathogenic or likely pathogenic variant (gBRCA) in both the metastatic and adjuvant setting.
Retrospective interpretation of sequenced data in light of the current literature is a major concern of the field. Such reinterpretation is manual and both human resources and variable operating procedures are the main bottlenecks.
The huge body of publicly available RNA-sequencing (RNA-seq) libraries is a treasure of functional information allowing to quantify the expression of known or novel transcripts in tissues.
Osteoarthritis (OA) is the most common joint disease worldwide. The etiology of OA is varied, ranging from multifactorial to environmental to monogenic.
We introduce a k-mer-based computational protocol, DE-kupl, for capturing local RNA variation in a set of RNA-seq libraries, independently of a reference gen...
The evolution of next-generation sequencing (NGS) technologies has led to increased focus on RNA-Seq. Many bioinformatic tools have been developed for RNA-Seq analysis, each with unique performance characteristics and configuration parameters.
